Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.H.S., Duke University School of Medicine 2019
  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2009 - 2012
  • M.D., Harvard Medical School 2009
• 

  Previous Appointments & Affiliations

  • Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2015 - 2021
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2021
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2017 - 2021
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
• Research
• 

  Selected Grants

  • NeoImmune NMTNT110 awarded by NeoImmuneTech, Inc. 2020 - 2025
  • Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer awarded by H. Lee Moffitt Cancer Center & Research Institute 2019 - 2022
  • Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer awarded by V Foundation for Cancer Research 2016 - 2022
  • The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies awarded by National Institutes of Health 2020 - 2022
  • A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512) awarded by Pfizer, Inc. 2016 - 2021
  • Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers awarded by V Foundation for Cancer Research 2019 - 2021
  • Validation of Prostate Cancer Stem Cell Model in First and Second Line Hormone Therapy awarded by H. Lee Moffitt Cancer Center & Research Institute 2018 - 2021
  • Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma awarded by Astellas Pharma Global Development, Inc 2016 - 2021
  • Immune correlates of immunotherapy responses in renal cell carcinoma awarded by Kidney Cancer Association 2019 - 2021
  • A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients awarded by Novartis Pharmaceuticals Corporation 2015 - 2021
  • A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer awarded by Cantex Pharmaceuticals, Inc. 2017 - 2021
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2021
  • Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells awarded by Janssen Research & Development, LLC 2016 - 2021
  • An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors awarded by AbbVie Inc. 2017 - 2020
  • A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected awarded by Regeneron Pharmaceuticals, Inc. 2016 - 2020
  • MM-310-01-01-01: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors awarded by Merrimack Pharmaceuticals 2017 - 2020
  • A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors awarded by OmniSeq, Inc 2017 - 2019
  • A study is to develop a retrospective database to study the PGDx TMB +MSI assay associated with clinical responses to immune checkpoint inhibitors (CPIs) awarded by Personal Genome Diagnostics, Inc. 2017 - 2019
  • Retrospective analysis of docetaxel in castration sensitive setting awarded by H. Lee Moffitt Cancer Center & Research Institute 2017 - 2019
• 

  External Relationships

  • ASCO
  • AbbVie Pharmaceuticals
  • Archimmune Therapeutics
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Calithera
  • Capio Biosciences
  • Dendreon Corporation
  • Exelixis, Inc.
  • Foundation medicine
  • Genomic Health, Inc.
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • MJH Associates
  • Merck
  • Merrimack Pharmaceuticals, Inc.
  • Novartis
  • OmniSeq
  • Pacific Genuity
  • Pfizer Inc.
  • Roche/Genentech
  • Sanofi-Aventis
  • Seattle Genetics
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.
       Full Text  Link to Item
    • Kao, Chester, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, and Jeffrey M. Clarke. “Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.” Clin Lung Cancer 22, no. 6 (November 2021): 500–509. https://doi.org/10.1016/j.cllc.2021.03.017.
       Full Text  Link to Item
    • Pal, Sumanta K., Paul H. Frankel, Amir Mortazavi, Matthew Milowsky, Ulka Vaishampayan, Mamta Parikh, Yung Lyou, et al. “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.” Jama Oncol 7, no. 10 (October 1, 2021): 1536–43. https://doi.org/10.1001/jamaoncol.2021.3441.
       Full Text  Link to Item
    • Rose, Tracy L., Michael R. Harrison, Allison M. Deal, Sundhar Ramalingam, Young E. Whang, Blaine Brower, Mary Dunn, et al. “Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.” J Clin Oncol 39, no. 28 (October 1, 2021): 3140–48. https://doi.org/10.1200/JCO.21.01003.
       Full Text  Link to Item
    • Spees, Lisa P., Stephanie B. Wheeler, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.” Cancer Med 10, no. 19 (October 2021): 6653–65. https://doi.org/10.1002/cam4.4201.
       Full Text  Link to Item
    • Zhu, Shaoming, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, and Chong-Xian Pan. “Combination strategies to maximize the benefits of cancer immunotherapy.” J Hematol Oncol 14, no. 1 (September 27, 2021): 156. https://doi.org/10.1186/s13045-021-01164-5.
       Full Text  Link to Item
    • Brady-Nicholls, Renee, Jingsong Zhang, Tian Zhang, Andrew Z. Wang, Robert Butler, Robert A. Gatenby, and Heiko Enderling. “Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.” Neoplasia 23, no. 9 (September 2021): 851–58. https://doi.org/10.1016/j.neo.2021.06.013.
       Full Text  Link to Item
    • Brown, Landon C., Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe C. Ornstein, and Tian Zhang. “Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.” J Immunother Cancer 9, no. 9 (September 2021). https://doi.org/10.1136/jitc-2021-003281.
       Full Text  Link to Item
    • Desai, Kunal, Landon Brown, Wei Wei, Matthew Tucker, Chester Kao, Emily Kinsey, Brian Rini, Kathryn Beckermann, Tian Zhang, and Moshe C. Ornstein. “A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.” Target Oncol 16, no. 5 (September 2021): 633–42. https://doi.org/10.1007/s11523-021-00832-3.
       Full Text  Link to Item
    • George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.
       Full Text  Link to Item
    • Wheeler, Stephanie B., Lisa P. Spees, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.” Jco Oncol Pract, June 17, 2021, OP2001082. https://doi.org/10.1200/OP.20.01082.
       Full Text  Link to Item
    • Grivas, P., A. R. Khaki, T. M. Wise-Draper, B. French, C. Hennessy, C. -. Y. Hsu, Y. Shyr, et al. “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.” Ann Oncol 32, no. 6 (June 2021): 787–800. https://doi.org/10.1016/j.annonc.2021.02.024.
       Full Text  Link to Item
    • Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol 16, no. 6 (June 2021): 743–44. https://doi.org/10.1038/s41565-021-00864-w.
       Full Text  Link to Item
    • Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.
       Full Text  Link to Item
    • Zhang, Tian, and Daniel J. George. “Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.” Nat Med 27, no. 4 (April 2021): 586–88. https://doi.org/10.1038/s41591-021-01320-x.
       Full Text  Link to Item
    • Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.
       Full Text  Link to Item
    • Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.
       Full Text  Open Access Copy  Link to Item
    • Dinan, Michaela A., Mihaela V. Georgieva, Yanhong Li, Tian Zhang, Michael Harrison, Rahul Shenolikar, and Charles D. Scales. “Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.” J Geriatr Oncol 12, no. 2 (March 2021): 298–304. https://doi.org/10.1016/j.jgo.2020.08.005.
       Full Text  Link to Item
    • Kao, Chester, Daniel J. George, and Tian Zhang. “An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).” Oncologist 26, no. 3 (March 2021): e508–11. https://doi.org/10.1002/onco.13617.
       Full Text  Link to Item
    • Hwang, Joyce K., Tian Zhang, Andrew Z. Wang, and Zihai Li. “COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.” J Hematol Oncol 14, no. 1 (February 27, 2021): 38. https://doi.org/10.1186/s13045-021-01046-w.
       Full Text  Link to Item
    • Pal, Sumanta K., Catherine Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y. C. Heng, Brian Shuch, et al. “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.” Lancet 397, no. 10275 (February 20, 2021): 695–703. https://doi.org/10.1016/S0140-6736(21)00152-5.
       Full Text  Link to Item
    • Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14. https://doi.org/10.1186/s40364-021-00267-y.
       Full Text  Link to Item
    • Nelson, A. A., R. J. Cronk, E. A. Lemke, A. Szabo, A. R. Khaki, L. N. Diamantopoulos, P. Grivas, et al. “Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.” Bladder Cancer 7, no. 1 (January 1, 2021): 33–42. https://doi.org/10.3233/BLC-200377.
       Full Text
    • Hwang, Joyce K., Neeraj Agarwal, James Brugarolas, and Tian Zhang. “Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.” Clin Cancer Res 27, no. 1 (January 1, 2021): 5–7. https://doi.org/10.1158/1078-0432.CCR-20-3506.
       Full Text  Link to Item
    • Wilson, Lauren E., Lisa Spees, Jessica Pritchard, Melissa A. Greiner, Charles D. Scales, Christopher D. Baggett, Deborah Kaye, et al. “Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.” Kidney Cancer 5, no. 3 (2021): 115–27. https://doi.org/10.3233/KCA-210119.
       Full Text  Link to Item
    • COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, Vincent A., and Vincent A. COVID-19 and Cancer Consortium. “A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.” Cancer Cell 38, no. 6 (December 14, 2020): 761–66. https://doi.org/10.1016/j.ccell.2020.10.022.
       Full Text  Link to Item
    • Brown, Landon C., Kunal Desai, Tian Zhang, and Moshe C. Ornstein. “The Immunotherapy Landscape in Renal Cell Carcinoma.” Biodrugs 34, no. 6 (December 2020): 733–48. https://doi.org/10.1007/s40259-020-00449-4.
       Full Text  Link to Item
    • Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
       Full Text  Link to Item
    • Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.
       Full Text  Open Access Copy  Link to Item
    • Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew Armstrong. “CLINICAL TRIALS IN PROGRESS.” Oncology New York 34, no. 8 (August 2020): 304–304.
       Link to Item
    • Kuderer, Nicole M., Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, et al. “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.” Lancet 395, no. 10241 (June 20, 2020): 1907–18. https://doi.org/10.1016/S0140-6736(20)31187-9.
       Full Text  Link to Item
    • Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.
       Full Text  Link to Item
    • Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.
       Full Text  Link to Item
    • Brady-Nicholls, Renee, John D. Nagy, Travis A. Gerke, Tian Zhang, Andrew Z. Wang, Jingsong Zhang, Robert A. Gatenby, and Heiko Enderling. “Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.” Nat Commun 11, no. 1 (April 9, 2020): 1750. https://doi.org/10.1038/s41467-020-15424-4.
       Full Text  Link to Item
    • Zhang, Tian, and Daniel J. George. “Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.” Clin Adv Hematol Oncol 18, no. 4 (April 2020): 204–7.
       Link to Item
    • Labriola, Matthew Kyle, Jason Zhu, Rajan T. Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.
       Full Text  Link to Item
    • Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol, February 13, 2020. https://doi.org/10.1016/j.euo.2020.01.005.
       Full Text  Link to Item
    • Marshall, Ariela L., Renee K. Dversdal, Martina Murphy, Donna M. Prill, Tian Zhang, and Shikha Jain. “WOMENtorship: The #WomenInMedicine perspective.” Med Teach 42, no. 2 (February 2020): 228–30. https://doi.org/10.1080/0142159X.2019.1671967.
       Full Text  Link to Item
    • Zhang, Tian, Lawrence I. Karsh, Michael J. Nissenblatt, and Steven E. Canfield. “Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.” Clin Genitourin Cancer 18, no. 1 (February 2020): 1–10. https://doi.org/10.1016/j.clgc.2019.09.015.
       Full Text  Link to Item
    • Armstrong, Andrew J., Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Patrick Healy, et al. “Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.” Jco Precis Oncol 4 (2020). https://doi.org/10.1200/PO.20.00200.
       Full Text  Link to Item
    • Zhang, Tian, Joyce K. Hwang, Daniel J. George, and Sumanta K. Pal. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.” Cancer Treat Res Commun 24 (2020): 100183. https://doi.org/10.1016/j.ctarc.2020.100183.
       Full Text  Link to Item
    • Mi, Yu, Feifei Yang, Cameron Bloomquist, Youli Xia, Bo Sun, Yanfei Qi, Kyle Wagner, Stephanie A. Montgomery, Tian Zhang, and Andrew Z. Wang. “Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.” Advanced Science (Weinheim, Baden Wurttemberg, Germany) 6, no. 19 (October 2019): 1900809. https://doi.org/10.1002/advs.201900809.
       Full Text
    • Wang, Hong, Lu Mao, Tian Zhang, Liming Zhang, Yuteng Wu, Wei Guo, Jingzhou Hu, Houyu Ju, and Guoxin Ren. “Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.” J Oral Pathol Med 48, no. 8 (September 2019): 669–76. https://doi.org/10.1111/jop.12883.
       Full Text  Link to Item
    • Zhang, Tian, Hoyin Lip, Chunsheng He, Ping Cai, Zhigao Wang, Jeffrey T. Henderson, Andrew M. Rauth, and Xiao Yu Wu. “Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.” Adv Healthc Mater 8, no. 18 (September 2019): e1900543. https://doi.org/10.1002/adhm.201900543.
       Full Text  Link to Item
    • Kao, Chester, Megan McNamara, Chris Alley, Neil Spector, Shekeab Jauhari, Rajan T. Gupta, Tian Zhang, and Jason Zhu. “A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.” Clin Genitourin Cancer 17, no. 3 (June 2019): e672–77. https://doi.org/10.1016/j.clgc.2019.03.019.
       Full Text  Link to Item
    • Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.
       Full Text  Link to Item
    • Zhang, Tian, Daniel J. George, and Andrew J. Armstrong. “Precision Medicine Approaches When Prostate Cancer Akts Up.” Clin Cancer Res 25, no. 3 (February 1, 2019): 901–3. https://doi.org/10.1158/1078-0432.CCR-18-2491.
       Full Text  Link to Item
    • Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.” J Immunother Cancer 7, no. 1 (January 24, 2019): 18. https://doi.org/10.1186/s40425-018-0489-5.
       Full Text  Link to Item
    • Wang, Zhigao, Rui Xue Zhang, Tian Zhang, Chunsheng He, Rong He, Xingrong Ju, and Xiao Yu Wu. “In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer.” Acs Appl Mater Interfaces 10, no. 48 (December 5, 2018): 41056–69. https://doi.org/10.1021/acsami.8b14001.
       Full Text  Link to Item
    • Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies.” Precis Clin Med 1, no. 3 (December 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.
       Full Text  Link to Item
    • Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.” Angew Chem Int Ed Engl 57, no. 39 (September 24, 2018): 12780–84. https://doi.org/10.1002/anie.201807582.
       Full Text  Link to Item
    • Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.” Clin Genitourin Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.
       Full Text  Link to Item
    • Myung, Ja Hye, Michael J. Eblan, Joseph M. Caster, Sin-Jung Park, Michael J. Poellmann, Kyle Wang, Kevin A. Tam, et al. “Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.” Clin Cancer Res 24, no. 11 (June 1, 2018): 2539–47. https://doi.org/10.1158/1078-0432.CCR-17-3078.
       Full Text  Link to Item
    • Zhang, Rui Xue, Jason Li, Tian Zhang, Mohammad A. Amini, Chunsheng He, Brian Lu, Taksim Ahmed, HoYin Lip, Andrew M. Rauth, and Xiao Yu Wu. “Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.” Acta Pharmacol Sin 39, no. 5 (May 2018): 825–44. https://doi.org/10.1038/aps.2018.33.
       Full Text  Link to Item
    • Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?” Prostate Cancer Prostatic Dis 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.
       Full Text  Link to Item
    • Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays.” Adv Drug Deliv Rev 125 (February 1, 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
       Full Text  Link to Item
    • Koshkin, Vadim S., Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, et al. “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.” J Immunother Cancer 6, no. 1 (January 29, 2018): 9. https://doi.org/10.1186/s40425-018-0319-9.
       Full Text  Open Access Copy  Link to Item
    • Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.” J Immunother Cancer 6, no. 1 (January 25, 2018): 4. https://doi.org/10.1186/s40425-018-0314-1.
       Full Text  Open Access Copy  Link to Item
    • Tian, Xi, Michael E. Werner, Kyle C. Roche, Ariel D. Hanson, Henry P. Foote, Stephanie K. Yu, Samuel B. Warner, et al. “Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.” Nat Biomed Eng 2 (2018): 443–52.
       Link to Item
    • Wang, Z., C. Zhang, T. Zhang, X. Ju, and R. He. “Effects of acylation and glycation treatments on physicochemical and gelation properties of rapeseed protein isolate.” Rsc Advances 8, no. 70 (January 1, 2018): 40395–406. https://doi.org/10.1039/C8RA07912A.
       Full Text
    • Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.
       Full Text  Open Access Copy  Link to Item
    • Zhang, Rui Xue, Tian Zhang, King Chen, Ji Cheng, Paris Lai, Andrew M. Rauth, K Sandy Pang, and Xiao Yu Wu. “Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.” J Vis Exp, no. 128 (October 5, 2017). https://doi.org/10.3791/56159.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol 35, no. 28 (October 1, 2017): 3175–77. https://doi.org/10.1200/JCO.2017.74.7931.
       Full Text  Link to Item
    • Humeniuk, Michael S., Tian Zhang, and Andrew J. Armstrong. “Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.” Cancer 123, no. 18 (September 15, 2017): 3441–44. https://doi.org/10.1002/cncr.30806.
       Full Text  Link to Item
    • Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol 12, no. 9 (September 2017): 877–82. https://doi.org/10.1038/nnano.2017.113.
       Full Text  Link to Item
    • Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.
       Full Text  Link to Item
    • Zhang, Tian, Preethy Prasad, Ping Cai, Chunsheng He, Dan Shan, Andrew Michael Rauth, and Xiao Yu Wu. “Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.” Acta Pharmacol Sin 38, no. 6 (June 2017): 835–47. https://doi.org/10.1038/aps.2016.166.
       Full Text  Link to Item
    • Tian, Jing, Yuangzeng Min, Zachary Rodgers, Xiaomeng Wan, Hui Qiu, Yu Mi, Xi Tian, et al. “Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.” Nanomedicine 13, no. 3 (April 2017): 1301–7. https://doi.org/10.1016/j.nano.2016.11.007.
       Full Text  Link to Item
    • Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies.” Future Oncol 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.
       Full Text  Link to Item
    • He, Chunsheng, Ping Cai, Jason Li, Tian Zhang, Lucy Lin, Azhar Z. Abbasi, Jeffrey T. Henderson, Andrew Michael Rauth, and Xiao Yu Wu. “Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.” J Control Release 246 (January 28, 2017): 98–109. https://doi.org/10.1016/j.jconrel.2016.12.019.
       Full Text  Link to Item
    • Ma, X., Y. Wu, T. Zhang, H. Song, H. Jv, W. Guo, and G. Ren. “Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases.” Journal of Cancer 8, no. 18 (January 1, 2017): 3828–37. https://doi.org/10.7150/jca.20935.
       Full Text
    • Ma, X., Y. Wu, T. Zhang, H. Song, H. Jv, W. Guo, and G. Ren. “The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.” Oncotarget 8, no. 47 (January 1, 2017): 82661–73. https://doi.org/10.18632/oncotarget.19746.
       Full Text
    • Zhang, Tian, Jun Gong, Manuel Caitano Maia, and Sumanta K. Pal. “Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.” Am Soc Clin Oncol Educ Book 37 (2017): 337–42. https://doi.org/10.1200/EDBK_175572.
       Full Text  Link to Item
    • Caster, Joseph M., Artish N. Patel, Tian Zhang, and Andrew Wang. “Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.” Wiley Interdiscip Rev Nanomed Nanobiotechnol 9, no. 1 (January 2017). https://doi.org/10.1002/wnan.1416.
       Full Text  Link to Item
    • Tian, Xi, Samuel B. Warner, Kyle T. Wagner, Joseph M. Caster, Tian Zhang, Patricia Ohana, Alberto A. Gabizon, and Andrew Z. Wang. “Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.” Int J Radiat Oncol Biol Phys 96, no. 3 (November 1, 2016): 547–55. https://doi.org/10.1016/j.ijrobp.2016.06.2457.
       Full Text  Link to Item
    • Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.” Urologic Oncology 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.
       Full Text
    • Shao, Zhiying, Andrew Z. Wang, Daniel J. George, and Tian Zhang. “Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.” Asian J Urol 3, no. 4 (October 2016): 268–77. https://doi.org/10.1016/j.ajur.2016.08.013.
       Full Text  Link to Item
    • Ware, Kathryn E., Jason A. Somarelli, Daneen Schaeffer, Jing Li, Tian Zhang, Sally Park, Steven R. Patierno, et al. “Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.” Oncotarget 7, no. 31 (August 2, 2016): 50507–21. https://doi.org/10.18632/oncotarget.10476.
       Full Text  Open Access Copy  Link to Item
    • Hu, Rachel, Daniel J. George, and Tian Zhang. “What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.” Ther Adv Urol 8, no. 4 (August 2016): 272–78. https://doi.org/10.1177/1756287216645314.
       Full Text  Link to Item
    • Kamal, Arif, Tian Zhang, Steve Power, and P Kelly Marcom. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.” J Natl Compr Canc Netw 14, no. 8 (August 2016): 993–98. https://doi.org/10.6004/jnccn.2016.0106.
       Full Text  Link to Item
    • Zhang, Rui Xue, Ping Cai, Tian Zhang, King Chen, Jason Li, Ji Cheng, K Sandy Pang, Hibret A. Adissu, Andrew M. Rauth, and Xiao Yu Wu. “Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.” Nanomedicine 12, no. 5 (July 2016): 1279–90. https://doi.org/10.1016/j.nano.2015.12.383.
       Full Text  Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
       Full Text  Open Access Copy  Link to Item
    • Au, Kin Man, Andrew Satterlee, Yuanzeng Min, Xi Tian, Young Seok Kim, Joseph M. Caster, Longzhen Zhang, Tian Zhang, Leaf Huang, and Andrew Z. Wang. “Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.” Biomaterials 82 (March 2016): 178–93. https://doi.org/10.1016/j.biomaterials.2015.12.018.
       Full Text  Link to Item
    • Zhu, Jason, Carter T. Davis, Sandra Silberman, Neil Spector, and Tian Zhang. “A role for the androgen receptor in the treatment of male breast cancer.” Crit Rev Oncol Hematol 98 (February 2016): 358–63. https://doi.org/10.1016/j.critrevonc.2015.11.013.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.” Curr Oncol Rep 18, no. 1 (January 2016): 3. https://doi.org/10.1007/s11912-015-0490-9.
       Full Text  Link to Item
    • Zhu, Jason, Tian Zhang, Radhika Shah, Arif H. Kamal, and Michael J. Kelley. “Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.” J Cancer Educ 30, no. 4 (December 2015): 774–78. https://doi.org/10.1007/s13187-015-0798-z.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew J. Armstrong. “Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.” Clin Cancer Res 21, no. 20 (October 15, 2015): 4505–7. https://doi.org/10.1158/1078-0432.CCR-15-1613.
       Full Text  Open Access Copy  Link to Item
    • Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.
       Full Text  Link to Item
    • Zhang, Tian, Elizabeth L. Boswell, Shannon J. McCall, and David S. Hsu. “Mismatch repair gone awry: Management of Lynch syndrome.” Crit Rev Oncol Hematol 93, no. 3 (March 2015): 170–79. https://doi.org/10.1016/j.critrevonc.2014.10.005.
       Full Text  Link to Item
    • Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.” Expert Opin Pharmacother 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.
       Full Text  Link to Item
    • Aggarwal, Rahul, Tian Zhang, Eric J. Small, and Andrew J. Armstrong. “Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.” J Natl Compr Canc Netw 12, no. 5 (May 2014): 719–26. https://doi.org/10.6004/jnccn.2014.0073.
       Full Text  Link to Item
    • Boggan, Joel C., Tian Zhang, Chris Derienzo, Karen Frush, and Kathryn Andolsek. “Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort.” J Grad Med Educ 5, no. 4 (December 2013): 652–57. https://doi.org/10.4300/JGME-D-12-00287.
       Full Text  Open Access Copy  Link to Item
    • Zhang, Tian, Shiva K. Das, Diane R. Fels, Katherine S. Hansen, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.” Ajr Am J Roentgenol 201, no. 5 (November 2013): W698–706. https://doi.org/10.2214/AJR.12.9698.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew J. Armstrong. “Clinical phenotypes of castration-resistant prostate cancer.” Clin Adv Hematol Oncol 11, no. 11 (November 2013): 707–18.
       Link to Item
    • Zhang, Tian, Andrew Schneider, Erika P. Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, and Jeffrey M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” Breast Cancer Res Treat 139, no. 3 (June 2013): 845–50. https://doi.org/10.1007/s10549-013-2590-2.
       Full Text  Link to Item
    • DeRienzo, Christopher M., Karen Frush, Michael E. Barfield, Priya R. Gopwani, Brian C. Griffith, Xiaoyin Jiang, Ankit I. Mehta, et al. “Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements.” Acad Med 87, no. 4 (April 2012): 403–10. https://doi.org/10.1097/ACM.0b013e318248e5c2.
       Full Text  Link to Item
    • Werner, Michael E., Shrirang Karve, Rohit Sukumar, Natalie D. Cummings, Jonathan A. Copp, Ronald C. Chen, Tian Zhang, and Andrew Z. Wang. “Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.” Biomaterials 32, no. 33 (November 2011): 8548–54. https://doi.org/10.1016/j.biomaterials.2011.07.067.
       Full Text  Link to Item
    • Zhang, Tian, Diane R. Fels, Katherine S. Hansen, Shiva K. Das, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER.” Journal of Thoracic Oncology 6, no. 6 (June 1, 2011): S919–20.
       Link to Item
    • Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2590.
       Link to Item
    • Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): e13048.
       Link to Item
    • Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 6104.
       Link to Item
    • Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 1046.
       Link to Item
    • Kinsey, Emily N., Tian Zhang, and Andrew J. Armstrong. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.” Cancer J 26, no. 1 (n.d.): 64–75. https://doi.org/10.1097/PPO.0000000000000418.
       Full Text  Link to Item
    • Brown, Landon C., Tian Zhang, and Daniel J. George. “The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.” Cancer J 26, no. 5 (n.d.): 376–81. https://doi.org/10.1097/PPO.0000000000000469.
       Full Text  Link to Item

  • Book Sections

    • Zhang, T., and A. Z. Wang. “Biochemical failure in prostate cancer.” In Prostate Cancer: A Comprehensive Perspective, 807–11, 2013. https://doi.org/10.1007/978-1-4471-2864-9_67.
       Full Text

  • Conference Papers

    • Barata, Pedro C., Shuchi Gulati, Andrew Elliott, Arpit Rao, Hans J. Hammers, David I. Quinn, Benjamin Adam Gartrell, et al. “Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).” In Journal of Clinical Oncology, 39:343–343. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.343.
       Full Text
    • Brown, Landon Carter, Susan Halabi, Michael Sandon Humeniuk, Yuan Wu, Taofik Oyekunle, Jiaoti Huang, Monika Anand, et al. “Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.” In Journal of Clinical Oncology, 39:89–89. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.89.
       Full Text
    • Dinan, Michaela Ann, Lauren E. Wilson, Melissa A. Greiner, Lisa Spees, Jessica Pritchard, Tian Zhang, Deborah Kaye, Daniel J. George, Charles D. Scales, and Stephanie B. Wheeler. “Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 39:280–280. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.280.
       Full Text
    • Harrison, Michael Roger, David Bartlett, Tian Zhang, Andrew J. Armstrong, Aubrie Coburn, Brian Coyne, Monika Anand, et al. “ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 39:300–300. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.300.
       Full Text
    • Mesleh Shayeb, Akram, Danielle Urman, Nazli Dizman, Luis A. Meza, Akhilesh Sivakumar, Chun Loo Gan, Hannah Elizabeth Dzimitrowicz, et al. “Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).” In Journal of Clinical Oncology, 39:291–291. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.291.
       Full Text
    • Pal, Sumanta K., Catherine Tangen, Ian Murchie Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng, Brian M. Shuch, et al. “Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.” In Journal of Clinical Oncology, 39:270–270. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.270.
       Full Text
    • Rose, Tracy L., Michael Roger Harrison, Allison Mary Deal, Chelsea K. Osterman, Sundhar Ramalingam, Young E. Whang, Blaine Y. Brower, et al. “Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).” In Journal of Clinical Oncology, 39:396–396. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.396.
       Full Text
    • Tucker, Matthew D., Andrew Lachlan Schmidt, Chih-Yuan Hsu, Yu Shyr, Andrew J. Armstrong, Ziad Bakouny, Christina Hunter Chapman, et al. “Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).” In Journal of Clinical Oncology, 39:39–39. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.39.
       Full Text
    • Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Luke T. Nordquist, et al. “Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).” In Journal of Clinical Oncology, 39:90–90. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.90.
       Full Text
    • Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, 39:TPS366–TPS366. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.tps366.
       Full Text
    • Lin, Chia-Chi, Elena Garralda, Patrick Schöffski, David Hong, Lillian Siu, Miguel Martin, Michela Maur, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” In Journal for Immunotherapy of Cancer, 8:A412–A412. BMJ, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0387.
       Full Text
    • Wilson, Lauren E., Lisa Spees, Jessica Pritchard, Melissa A. Greiner, Charles D. Scales, Chris Baggett, Deborah Kaye, et al. “Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Msaouel, P., A. O. Siefker-Radtke, R. Sweis, S. Mao, J. E. Rosenberg, U. N. Vaishampayan, A Rezazadeh Kalebasty, et al. “705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).” In Annals of Oncology, 31:S556–S556. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.777.
       Full Text
    • Bu, Jiyoon, Michael J. Poellmann, Marco Reyes-Martinez, Andrew Armstrong, Daniel George, Tian Zhang, Andrew Z. Wang, and seungpyo hong. “Abstract 6439: CapioCyte™ technology for efficient capture and downstream analysis of circulating tumor cells from renal cell carcinoma.” In Clinical Trials. American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.am2020-6439.
       Full Text
    • Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Eric Jonasch, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient preferences and expectations of systemic therapy in renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Campbell, Matthew T., Tian Zhang, Lynda Chin, Allison Betof Warner, and Matthen Mathew. “ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Garmezy, Benjamin, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, et al. “Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Watson, Catherine, Sarah Tait, Lindsay Soo, Jennifer Kay Plichta, Tian Zhang, Edgardo Castellar, Andrew J. Armstrong, et al. “The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Agarwal, Anika, Jennifer Modliszewski, Lauren Davey, Marco Reyes-Martinez, Daniella Runyambo, David Corcoran, Holly Dressman, et al. “Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Battle, Dena, Wendy Kimryn Rathmell, Eric Jonasch, Pavlos Msaouel, Adam P. Stern, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Brown, Landon Carter, Kunal Desai, Chester Kao, Emily Noelle Kinsey, Patrick Healy, Julie Kephart, Michael Roger Harrison, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Desai, Kunal, Landon Carter Brown, Wei Wei, Kimberly D. Allman, Allison Martin, Laura S. Wood, Shilpa Gupta, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Kao, Chester, Eric Powers, Michael B. Datto, Michelle Green, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Jeffrey Melson Clarke, John H. Strickler, and Tian Zhang. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
       Link to Item
    • Brown, Landon, Emily Kinsey, Chester Kao, Patrick Healy, Andrew Armstrong, Megan McNamara, Sundhar Ramalingam, Michael Harrision, Daniel George, and Tian Zhang. “A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
       Link to Item
    • Kinsey, Emily, Landon Brown, Chester Kao, Patrick Healy, Michael Harrison, Megan McNamara, Andrew Armstrong, Sundhar Ramalingham, Daniel George, and Tian Zhang. “Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC).” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
       Link to Item
    • Choueiri, Toni K., David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, et al. “Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-ct162.
       Full Text
    • Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:e16079–e16079. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e16079.
       Full Text
    • Labriola, Matthew, Jason Zhu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:e14259–e14259. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14259.
       Full Text
    • Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.
       Full Text
    • Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.
       Full Text
    • Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, et al. “PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, 37:TPS4596–TPS4596. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps4596.
       Full Text
    • Zhu, Jason, Matthew D. Tucker, Chester Kao, Matthew Labriola, Sachica Cheris, Michael B. Datto, Yuan Wu, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants.” In Journal of Clinical Oncology, 37:e14291–e14291. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14291.
       Full Text
    • Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:2595–2595. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2595.
       Full Text
    • Glenn, Sean T., Sarabjot Pabla, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.” In Journal of Clinical Oncology, 37:62–62. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.62.
       Full Text
    • Pabla, Sarabjot, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, Edwin Yau, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.” In Journal of Clinical Oncology, 37:61–61. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.61.
       Full Text
    • Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:63–63. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.63.
       Full Text
    • Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.
       Full Text
    • Harrison, Michael Roger, Michel Khouri, Andrew J. Armstrong, Tian Zhang, Megan Ann McNamara, Monika Anand, Ellen Bratt, et al. “PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 37:281–281. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.281.
       Full Text
    • Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:589–589. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.589.
       Full Text
    • Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:400–400. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.400.
       Full Text
    • Tucker, Matthew D., Jason Zhu, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Roger Harrison, Yuan Wu, Patrick Healy, Daniel J. George, and Andrew J. Armstrong. “Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:172–172. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.172.
       Full Text
    • Zhang, Tian, Janet S. Staats, Cliburn Chan, Ajjai Shivaram Alva, Peter H. O’Donnell, Michael Roger Harrison, Kristen A. Batich, Veerendra Munugalavadla, Daniel J. George, and Kent J. Weinhold. “Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).” In Journal of Clinical Oncology, 37:357–357. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.357.
       Full Text
    • Zhu, Jason, Matthew Labriola, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:577–577. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.577.
       Full Text
    • Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:607–607. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.607.
       Full Text
    • Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
       Full Text
    • Ware, Kathryn E., Santosh Gupta, Jared Eng, Wen-Chi Foo, Lorin Crawford, Garland Austin, Bhairavy Puviindran, et al. “Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer.” In Poster Presentations  Proffered Abstracts. American Association for Cancer Research, 2018. https://doi.org/10.1158/1538-7445.prca2017-b038.
       Full Text
    • George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
       Link to Item
    • Batich, Kristen A., Janet S. Staats, Cliburn Chan, Cecile Krejsa, Daniel J. George, Kent J. Weinhold, and Tian Zhang. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 36:e16519–e16519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e16519.
       Full Text
    • Choueiri, Toni K., David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, et al. “KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.” In Journal of Clinical Oncology, 36:TPS4599–TPS4599. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4599.
       Full Text
    • Ernstoff, Marc S., Wen Wee Ma, Frank Yung-Chin Tsai, Pamela N. Munster, Tian Zhang, Walid Kamoun, J Marc Pipas, Sharon Chen, Sergio Santillana, and Vasileios Askoxylakis. “A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.” In Journal of Clinical Oncology, 36:TPS2604–TPS2604. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps2604.
       Full Text
    • Hong, David S., Patrick Schoffski, Aitana Calvo, John Sarantopoulos, María Ochoa De Olza, Richard D. Carvajal, Amy Prawira, et al. “Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.” In Journal of Clinical Oncology, 36:3012–3012. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3012.
       Full Text
    • Sitlinger, Andrea Phillips, Rishi Sachdev, Peter A. Ubel, Charlene Wong, Thomas William LeBlanc, Tian Zhang, David Anderson, and Yousuf Zafar. “Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?” In Journal of Clinical Oncology, 36:6620–6620. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.6620.
       Full Text
    • Zhang, Tian, Janet S. Staats, Cliburn Chan, Michael Roger Harrison, Peter H. O’Donnell, Kristen A. Batich, Tianling Chen, et al. “Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).” In Journal of Clinical Oncology, 36:4533–4533. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4533.
       Full Text
    • Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:5059–5059. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5059.
       Full Text
    • Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
       Full Text
    • Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:191–191. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.191.
       Full Text
    • Choueiri, T. K., T. Powles, T. Zhang, D. I. Quinn, J. E. Gschwend, S. S. Wan, and C. Poehlein. “KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Zhang, T., M. Harrison, P. O’Donnell, A. Alva, N. Hahn, L. J. Appleman, J. Cetnar, et al. “Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Bakthavatsalam, Subha, Tian Zhang, and Katherine Franz. “Targeted prodrugs to manipulate copper biology of prostate cancer.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
       Link to Item
    • Dharani, Azim, Subha Bakthavatsalam, Tian Zhang, and Katherine Franz. “Prostate cancer targeted prodrug based on copper prochelator.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
       Link to Item
    • Ware, Kathryn E., Daneen Schaeffer, Tian Zhang, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Abstract 1847: AR-V7 regulation during epithelial plasticity.” In Endocrinology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-1847.
       Full Text
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
       Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.” In Journal of Clinical Oncology, 33:84–84. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.84.
       Full Text
    • Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.
       Full Text
    • Zhang, Tian, Steve Power, Paul K. Marcom, and Arif Kamal. “Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure.” In Journal of Clinical Oncology, 32:6503–6503. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6503.
       Full Text
    • Zhang, Tian, Arif Kamal, and Michael J. Kelley. “Comparison of QOPI measure conformance between oncology fellows and attending physicians.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.31_suppl.162.
       Full Text  Link to Item
    • Zhang, Tian, Shiva K. Das, Jeffrey Crawford, Terence Wong, Mark W. Dewhirst, and Gordana Vlahovic. “(62)cuatsm and (62)cuptsm PET is a useful imaging tool for hypoxia and perfusion in lung cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” In Journal of Clinical Oncology, 29:2590–2590. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.2590.
       Full Text
    • Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:e13048–e13048. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e13048.
       Full Text
    • Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:6104–6104. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6104.
       Full Text
    • Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” In Journal of Clinical Oncology, 29:1046–1046. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1046.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.